Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Merus

Merus Clears Technical Benchmark, Hitting 80-Plus RS Rating

Merus shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 76 to 81.

Investors Business Daily

Stocks To Watch: Merus Sees RS Rating Rise To 84

Merus shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 84.

Investors Business Daily

Stocks Showing Rising Market Leadership: Merus Earns 81 RS Rating

Merus shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 81.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics

Merus stock rocketed — and hammered Bicara — after unveiling promising new results for its experimental head-and-neck cancer treatment.

Investors Business Daily

IBD Rating Upgrades: Merus Shows Improved Price Strength

A Relative Strength Rating upgrade for Merus shows improving technical performance. Will it continue?

Investors Business Daily

Why Is Coherus BioSciences Stock Trading Higher On Tuesday?

Coherus sells Udenyca franchise for up to $558.4 million, shifts focus to immuno-oncology R&D, and plans clinical trials in hepatocellular carcinoma and NSCLC.

Benzinga

Why Top 4% Biotech Stock, Merus, Just Catapulted To A Record High

Merus stock catapulted to a record high Friday after its experimental regimen for head-and-neck cancer beat expectations in a key study.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

4 A-Rated Biotech Stocks Sparking Investor Interest

The biotech industry is rapidly evolving thanks to the surging biopharma M&A activity and incorporation of new technological trends like AI and gene editing. Given this backdrop, quality biotech stocks Gilead Sciences (GILD), Equillium (EQ), Incyte Corporation (INCY), and Jazz Pharmaceuticals plc (JAZZ), rated A (Strong Buy) overall in our…

StockNews.com

Merus Stock Joins Rank Of Stocks With RS Ratings Over 90

Merus shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

Needham Says Merus' ASCO Update On Zeno 'Positive'

Needham writes that Merus NV (NASDAQ: MRUS) has enough data to initiate an FDA marketing application filing in mid-2022 after presenting Zenocutuzumab (Zeno) data in NRG1-fusion (NRG1+) Cancer.

Benzinga

Incyte Pulls Parsaclisib US Application For Lymphoma Treatment, Bows Out Solid Tumor Program With Merus

Incyte Corporation (NASDAQ: INCY) is

Benzinga

People

Matt Phipps

10 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Investor Business Daily

Jazz Pharmaceuticals plc

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.